ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1500
-0.0300 (-0.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.1800
Open3.2300
Bid2.90 x 3200
Ask3.37 x 2200
Day's Range3.1100 - 3.2600
52 Week Range1.8400 - 3.9300
Volume581,444
Avg. Volume1,587,454
Market Cap496.254M
Beta (3Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.45
Trade prices are not sourced from all markets
  • Zacks Small Cap Research2 days ago

    ATRS: Xyosted & Epi Pen Available for Sale

    The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.

  • Should You Buy NanoString Technologies Inc (NSTG)?
    Insider Monkey3 days ago

    Should You Buy NanoString Technologies Inc (NSTG)?

    Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]

  • Is Noodles & Co (NDLS) A Good Stock To Buy?
    Insider Monkey7 days ago

    Is Noodles & Co (NDLS) A Good Stock To Buy?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • GlobeNewswire9 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies — New Research Emphasizes Economic Growth

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire13 days ago

    Antares Pharma Announces the Commercial Availability of XYOSTED™ (Testosterone Enanthate) Injection — A New Treatment for Adult Men Diagnosed With Testosterone Deficiency

    Antares Pharma, Inc. (ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. XYOSTED™ is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector.  XYOSTED™ has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (see Indications and Usage below).  XYOSTED™ was approved by the U.S. Food and Drug Administration (“FDA”) on September 28, 2018.

  • Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
    Zacks14 days ago

    Teva (TEVA) Launches First Generic Version of Mylan's EpiPen

    Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.

  • Teva's generic EpiPen hits the market in limited doses
    American City Business Journals15 days ago

    Teva's generic EpiPen hits the market in limited doses

    Teva Pharmaceutical Industries on Tuesday released limited doses of its generic version of EpiPen Auto-Injector. Its generic EpiPen, developed in a partnership with New Jersey-based Antares Pharma, is carrying a price tag of $300. Mylan has come under criticism by government agencies and consumers because of price increases that have driven up the cost of the branded EpiPen injector from less than $100 to more than $600 during the past decade.

  • GlobeNewswire15 days ago

    Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen®

    Antares Pharma, Inc. (ATRS) (“Antares”) today announced that Teva Pharmaceutical Industries, Ltd.’s (“Teva”) generic EpiPen® is now commercially available in limited quantities. Teva’s generic EpiPen® was approved by the U.S. Food and Drug Administration (“FDA”) on August 16, 2018 and is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. The product, which utilizes the Antares Pharma VIBEX® auto injector, has been approved as therapeutically equivalent and fully substitutable to the EpiPen® at the pharmacy.

  • Zacks Small Cap Research16 days ago

    ATRS: Xyosted Launch Before Year End

    Highlights for the quarter and quarter to date include FDA approval of Xyosted, FDA approval generic epinephrine pen and a new partnership with Pfizer (PFE). Strong sales of Makena at partner AMAG (AMAG) and optimism over a 2018 start to Xyosted sales were offset by weaker than expected sales for Otrexup and Sumatriptan. Antares Pharma, Inc. posted third quarter 2018 revenues of $17.9 million, representing 19% growth compared to prior year results of $15.1 million.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of ATRS earnings conference call or presentation 6-Nov-18 1:30pm GMT

    Q3 2018 Antares Pharma Inc Earnings Call

  • GuruFocus.com28 days ago

    Healthcare Value Capital, LLC Buys Antares Pharma Inc, Sells Novelion Therapeutics Inc

    Woodcliff Lake, NJ, based Investment company Healthcare Value Capital, LLC buys Antares Pharma Inc, sells Novelion Therapeutics Inc during the 3-months ended 2018-09-30, according to the most recent filings ...

  • GlobeNewswire29 days ago

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Antares Pharma, Inc. (ATRS) and Encourages ATRS Investors to Contact the Firm

    NEW YORK, Nov. 12, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Antares Pharma, Inc. (NASDAQ: ATRS)..

  • Business Wirelast month

    Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2016 and October 12, 2017.

  • GlobeNewswirelast month

    Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting

    XYOSTED™ AMBULATORY BLOOD PRESURE ABSTRACT HAS BEEN SELECTED FOR POSTER PRESENTATION EWING, N.J., Nov. 09, 2018 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that.

  • GlobeNewswirelast month

    Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday November 15, 2018 at 8:40 am (GMT) / 3:40 am (EST) in London, UK. Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Associated Presslast month

    Antares Pharma: 3Q Earnings Snapshot

    The Ewing, New Jersey-based company said it had a loss of 1 cent per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • GlobeNewswirelast month

    Antares Pharma Reports Third Quarter 2018 Operating and Financial Results

    The Company Posts Record Quarterly Revenue Of $17.9 Million EWING, N.J., Nov. 06, 2018 -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today announced operating and.

  • GlobeNewswirelast month

    Antares Pharma to Report Third Quarter 2018 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its third quarter 2018 financial results and recent operating progress before the market opens on Tuesday, November 6, 2018.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on November 6, 2018 to discuss the results.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Kohl's, Activision Blizzard, Amerco, Cree, Antares Pharma, and Uranium Energy — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.2 months ago

    Antares Pharma Inc’s (NASDAQ:ATRS) Path To Profitability

    Antares Pharma Inc’s (NASDAQ:ATRS): Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s loss has recently broadened since Read More...

  • Makena Auto Injector Is a Key Asset for Antares Pharma in 2018
    Market Realist2 months ago

    Makena Auto Injector Is a Key Asset for Antares Pharma in 2018

    In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.

  • Antares Pharma Is Expected to Report Positive EPS in 2019
    Market Realist2 months ago

    Antares Pharma Is Expected to Report Positive EPS in 2019

    In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis. Losses increased due to rising operating expenses and an unfavorable shift in product mix. The company reported operating expenses of $22.25 million in H1 2018, a YoY rise of 6%, which is mainly attributable to a 12% YoY rise in research and development expenses associated with pipeline products.

  • Antares Pharma Could Report Solid Revenue Growth in Fiscal 2018
    Market Realist2 months ago

    Antares Pharma Could Report Solid Revenue Growth in Fiscal 2018

    In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%. The revenue growth was mainly driven by a 27% YoY rise in product sales, which reached $22.04 million in H1 2018. Wall Street analysts expect Antares Pharma to report revenues of $59.56 million in fiscal 2018, which is a YoY rise of 9.25%.

  • Here’s Why Antares Pharma Stock Rose on October 2
    Market Realist2 months ago

    Here’s Why Antares Pharma Stock Rose on October 2

    Antares Pharma (ATRS) rose a solid 15.64% from $3.26 on October 1 to $3.77 on October 2. On October 1, 2018, the company announced that its Xyosted injection coupled with the QuickShot auto injector has gotten FDA approval as a testosterone replacement therapy in three dosage strengths of 50 mg, 75 mg, and 100 mg. As noted in Antares Pharma’s press release, Symphony Health Solutions has estimated the total number of retail prescriptions in the testosterone replacement market in 2017 at around 6.5 million. Antares Pharma closed at $3.77 on October 2, 2018, which was 138.61% higher than its 52-week low price of $1.58 and 7.82% lower than its 52-week high price of $4.09.